ALW-II-41-27 2 mg | 99.52%
TargetMol
ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
More Information Supplier PageALW-II-41-27
Search Results
SCH-23390 hydrochloride 5 mg | 99.07%
TargetMol
SCH 23390 hydrochloride is an effective dopamine receptor antagonist, and for the D1(Ki=0.2 nM) and D5(Ki=0.3 nM).
More Information Supplier PageSCH-23390 hydrochloride
SCH-23390 hydrochloride 2 mg | 99.07%
TargetMol
SCH 23390 hydrochloride is an effective dopamine receptor antagonist, and for the D1(Ki=0.2 nM) and D5(Ki=0.3 nM).
More Information Supplier PageSCH-23390 hydrochloride
SB756050 25 mg | 98.35%
TargetMol
SB756050
ALW-II-41-27 50 mg | 99.52%
TargetMol
ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
More Information Supplier PageALW-II-41-27
ALW-II-41-27 25 mg | 99.52%
TargetMol
ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
More Information Supplier PageALW-II-41-27
ALW-II-41-27 10 mg | 99.52%
TargetMol
ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
More Information Supplier PageALW-II-41-27
ALW-II-41-27 5 mg | 99.52%
TargetMol
ALW-II-41-27, an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy.
More Information Supplier PageALW-II-41-27
AG-494 5 mg | 98.90%
TargetMol
AG-494 (Tyrphostin B48) is an inhibitor of epidermal growth factor receptor kinase.
More Information Supplier PageAG-494
ML327 1 mg | 99.48%
TargetMol
ML327 is a MYC blocker. ML327 can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).
More Information Supplier PageML327
